POC 지질 검사 시장 기회, 성장 촉진요인, 산업 동향 분석 및 예측(2025-2034년)

The Global Point of Care Lipid Test Market was valued at USD 694.1 million in 2024 and is estimated to grow at a CAGR of 5.1% to reach USD 1.13 billion by 2034. This market encompasses portable diagnostic solutions designed to measure blood lipid levels, such as triglycerides and cholesterol, outside traditional laboratory settings. These tools provide real-time results, making them essential in clinical practice, general healthcare environments, and for personal use at home. The mounting global burden of cardiovascular conditions, which are often linked with abnormal lipid levels, continues to drive demand for easily accessible testing alternatives.

Rapid and user-friendly testing methods are becoming increasingly sought after as individuals seek to manage health proactively. With a greater emphasis on preventive care and early detection, there's been a noticeable push for reliable devices that are simple to operate and provide fast, accurate outcomes. Ongoing technological improvements are making these devices more precise and user-friendly, reinforcing their growing appeal. The move away from traditional diagnostics and toward on-demand lipid profiling reshape the healthcare landscape, as people demand control over their wellness without depending on conventional healthcare appointments.

In 2024, the consumables segment generated USD 401 million and is projected to grow at a 5% CAGR through 2034. The increasing global incidence of cardiovascular ailments, as highlighted by international health organizations, is a significant driver behind the surge in demand for lipid testing products. Consumables such as reagent cartridges and test strips are essential for every lipid profile test and are intended for single use, resulting in high repurchase frequency. As point-of-care diagnostics become more integrated into various healthcare environments like outpatient centers, primary care offices, and personal health setups, the necessity for reliable, disposable components is rising. The growing preference for fast, hygienic, and accurate testing solutions is enhancing the uptake of consumables.

The lipid and lipoprotein disorder segment accounted for the largest market share in 2024, holding 40.4% due to the rising prevalence of dyslipidemia, including genetic and acquired lipid imbalances. These disorders play a central role in the development of heart-related illnesses, which continue to be the foremost cause of mortality worldwide. The urgency of diagnosing and managing lipid irregularities reinforces the widespread use of point-of-care lipid panels. Medical professionals-particularly those specializing in internal medicine and cardiology-heavily rely on these tests to support early interventions. The demand for regular lipid monitoring has made these diagnostics a fundamental tool in both specialized and general healthcare.

United States Point of Care Lipid Test Market is anticipated to reach USD 440.4 million by 2034. Increasing public concern regarding cardiovascular risk has sparked widespread awareness about the importance of lipid testing, which is pushing the adoption of convenient, easy-to-use diagnostic kits. The shift toward immediate, at-home testing is accelerating as more individuals aim to manage their health proactively. The rising incidence of lipid disorders across the country is intensifying the need for dependable, accessible solutions. As awareness continues to grow, the market is benefiting from a surge in demand for compact diagnostic tools that allow regular screening without the need for formal lab visits.

Major industry participants driving innovation and expansion in the Global Point of Care Lipid Test Industry include F. Hoffmann-La Roche, VivaChek Biotech, Kanlife, Abbott Laboratories, SD Biosensor, Sinocare, Callegari, MiCoBio, Nova Biomedical, and Menarini Group. To strengthen their market positioning, key players are implementing strategies centered around continuous product innovation and technological enhancement. Companies are investing in the development of advanced diagnostic devices that deliver faster and more accurate results while enhancing user-friendliness. Many are expanding their geographic reach through partnerships and strategic collaborations with healthcare distributors and clinics. These alliances help improve accessibility to lipid testing kits across various markets.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
• 3.3 Growth drivers
  • 3.3.1 Increasing prevalence of cardiovascular diseases
  • 3.3.2 Rising shift towards preventive healthcare
  • 3.3.3 Technological advancements in POC lipid testing devices
  • 3.3.4 Growing adoption in emerging economies
• 3.4 Industry pitfalls and challenges
  • 3.4.1 Stringent regulatory scenario
  • 3.4.2 Limited awareness in rural areas
• 3.5 Growth potential analysis
• 3.6 Regulatory landscape
• 3.7 Technological landscape
• 3.8 Future market trends
• 3.9 Gap analysis
• 3.10 Porter's analysis
• 3.11 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Instruments
• 5.3 Consumables

Chapter 6 Market Estimates and Forecast, By Disease Indication, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Lipid and lipoprotein disorder
  • 6.2.1 Endogenous hyperlipemia
  • 6.2.2 Tangier disease
  • 6.2.3 Hyperlipoproteinemia
  • 6.2.4 Familial hypercholesterolemia
  • 6.2.5 Other lipid and lipoprotein disorders
• 6.3 Atherosclerosis
• 6.4 Liver and renal diseases
• 6.5 Diabetes mellitus
• 6.6 Other disease indication

Chapter 7 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals
• 7.3 Clinics
• 7.4 Diagnostic laboratories
• 7.5 Other end use

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 India
  • 8.4.3 Japan
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 South Africa
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 Abbott Laboratories
• 9.2 Callegari
• 9.3 F. Hoffmann-La Roche
• 9.4 Kanlife
• 9.5 Menarini Group
• 9.6 MiCoBio
• 9.7 Nova Biomedical
• 9.8 SD Biosensor
• 9.9 Sinocare
• 9.10 VivaChek Biotech